Table 4: Differentially expressed genes between patients with CD5+ and CD5− DLBCL.
Function categories | Numbers | Upregulated gene names | Numbers | Downregulated gene names |
---|---|---|---|---|
Antiapoptosis | 2 | BCL2, TNFAIP8 | ||
T-cell and B-cell receptor signaling | 7 | CARD11, CLECL1, IGHM, LYN, PTPN2, SIT1, SH3BP5ⱡ | ||
Hematopoietic development, immune response, central nervous system, signaling including NF-kB, MAPK, Wnt and calcium-dependent pathways | 10 | ARHGAP17, BSPRY, C2orf34ⱡ, CXXC5ⱡ, SIPA1L3ⱡ, OGT, MPEG1, OAS1ⱡ, TMEM149, GLYR1* | 14 | APCDD1ⱡ, CLEC11A, DZIP1, INHBA#x2C61;, PI15ⱡ, PDE4D, SGK1, SOBP, CAMK2N1*, FGF1*, FGF17*, PPM1L*, PTPRR*, SLC6A9* |
Cell cycle progression | 3 | CCND2, CDK3, TLK1 | 1 | NEK6ⱡ |
Transcriptional activator/repressor | 11 | CREB3L2, ETV6, FOXP1, IRF2BP2, JARID2, TCF4ⱡ, ZNF589, RBM39*, ANKRD12*, ZNF614*, ZNF814* | 7 | LMO2, LMO4, MAML3, TFEC, MYBL1, ZNF709, LHX2* |
mRNA stability, RNA regulation | 2 | LUC7L, SERBP1 | 1 | SREK1 |
Protein modification, processing, degradation, transporter | 3 | ERP29, FAM175Bⱡ, SLC38A2 | 2 | CTSK, UGGT2ⱡ |
Cytoskeletal protein, extracellular matrix, cell adhesion, migration | 1 | PDLIM1 | 14 | CCBE1, COL5A1, COL6A3, ENPP3, FAM198Bⱡ, FN1, LTBP1, PCDH9, PTK2, PTPRB, RAPH1, BAIAP2L1*, ITGBL1*, MYO7A* |
Metabolism | 1 | ST3GAL2* | ||
IncRNA, unknown function and others | 12 | C13orf18ⱡ, CXorf21, FAM129Cⱡ, LOC100506168, LOC202781, KLHL14, KIAA0040ⱡ, LIC7L, MAPS8, RRP7A, NPIP*, NAPSB* | 11 | CRNDE,CCDC144B, C15orf48, FRMD6, GLT1D1, LOC100288271ⱡ, LOC100506457ⱡ, LOC100133790ⱡ, LOC440864, KIAA1211, SAMD12, LOC100130815* |
Note: Genes marked by
are those identified in comparison of CD5+ vs. CD5− ABC-DLBCLs; genes marked by
are those identified in both CD5+ vs. CD5− DLBCL and CD5+ vs. CD5− ABC-DLBCL. Bolded genes are involved in nervous system development or function.